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A mechanistic model of tau amyloid aggregation
based on direct observation of oligomers
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Protein aggregation plays a key role in neurodegenerative disease, giving rise to small
oligomers that may become cytotoxic to cells. The fundamental microscopic reactions taking
place during aggregation, and their rate constants, have been difﬁcult to determine due to
lack of suitable methods to identify and follow the low concentration of oligomers over time.
Here we use single-molecule ﬂuorescence to study the aggregation of the repeat domain of
tau (K18), and two mutant forms linked with familial frontotemporal dementia, the deletion
mutant DK280 and the point mutant P301L. Our kinetic analysis reveals that aggregation
proceeds via monomeric assembly into small oligomers, and a subsequent slow structural
conversion step before ﬁbril formation. Using this approach, we have been able to quanti-
tatively determine how these mutations alter the aggregation energy landscape.
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T
he spontaneous aggregation of proteins to form larger
structures is a widespread and fundamental process in both
normal and aberrant biology. Formation of large insoluble
ﬁbrils, often via self-assembly of soluble protein into oligomeric
structures, is key to the pathology of several well-known human
conditions such as Parkinson’s disease1, prion disorders and
Alzheimer’s disease2. Alzheimer’s disease is characterized by the
deposition of two distinct types of aggregates—extracellular
plaques composed of Ab peptides (cleavage products of the
transmembrane protein APP) and intracellular neuroﬁbrillary
tangles composed of hyperphosphorylated tau protein. Tau is a
microtubule-binding protein that can aggregate into ﬁlaments,
which are amyloid in nature (based on cross-b structure) and are
the major constituents of neuroﬁbrillary tangles in the neurons of
Alzheimer-diseased brains3.
Tau proteins are broadly speaking divided into two domains—
a carboxyl-terminal microtubule-binding domain and an amino-
terminal projection domain4. The microtubule-binding domain is
positively charged overall, assisting its interaction with the
negatively charged surfaces of microtubules, and contains three
or four similar, but not identical, repeat regions of 31 or 32 amino
acids5 (Fig. 1). Tau is rich in polar amino acids, which renders it a
highly soluble protein with little secondary structure6 even once
bound to the microtubule7. At ﬁrst glance, it is therefore a
surprise that this protein assembles into amyloid structures.
However, hexapeptide motifs, which are present in two of the
four repeat regions of the microtubule-binding domain, have a
high b-sheet-forming propensity8. These have been demonstrated
to be fundamental to the aggregation process, and form the core
of the ﬁlaments8,9. Aggregation of full-length tau in vitro is
indeed generally slow because of the charged, highly soluble
nature of the protein10. In vitro aggregation studies have therefore
tended to focus on constructs formed from the aggregation-prone
repeat domain of the microtubule-binding domain (K18 and
K19), which aggregate faster without the presence of the ﬂanking
regions11. In addition, polyanion cofactors such as heparin and
RNA have been found to accelerate aggregation, presumably by
interacting with tau and compensating for the positive charges
of the tau molecules, creating less unfavorable long-range
electrostatic forces between tau molecules, and increasing the
local tau concentration6,12–14. Heparin has traditionally been
used to initiate aggregation within in vitro tau aggregation
studies14.
Until relatively recently, only average populations of ﬁbrils
were readily accessible in both in vivo and in vitro experiments,
with transient oligomer populations proving much more difﬁcult
to detect15. To date, most theoretical modelling and
understanding has thus focused on describing ﬁbril formation,
leading to some successful analytical treatments16,17. However,
recent developments in single-molecule ﬂuorescence techniques
have led to signiﬁcant advances in our ability to also detect the
formation of lowly populated oligomeric species. New theoretical
models are now desired that are capable of fully describing these
better-characterized aggregation kinetics, and quantifying them.
Although early single-molecule observations of synuclein
aggregation were described with a simple conversion model18,
an explicit kinetic treatment providing rate constants for all
microscopic steps in the entire aggregation reaction has not been
achieved to date. In this work, we have applied kinetic analysis to
single-molecule ﬂuorescence measurements to study the
aggregation of tau protein and determine the aggregation
pathway and the number and size of tau oligomers formed
during this process. This approach allows the detailed analysis
and quantiﬁcation of many aspects of aggregating systems that
may be difﬁcult to directly measure experimentally.
Results
Aggregation of K18 tau into paired helical ﬁlaments. We have
performed single-molecule ﬂuorescence studies of AlexaFluor-
488 and AlexaFluor-647 labeled tau proteins (K18 construct)
during their aggregation into ﬁlaments. This construct contains
the four repeated sequences in the microtubule-binding domain
that form the core of ﬁlaments and includes the two hexapeptide
motifs in repeats R2 and R3, which nucleate aggregation3. We
then compared its aggregation behaviour with that of a single
point deletion mutant (DK280), one of the tau mutations found
in frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17)19,20, and a single point mutation
mutant (P301L) that is the most common mutation associated
with FTDP-17 (ref. 21). Fluorophore-labelled tau constructs
based on the K18 tau construct were created (Fig. 1)10,11. Our
results from bulk studies indicate that the presence of the Alexa
label at residue 260 (outside the ﬁlament core) does not
signiﬁcantly affect the aggregation process; ﬁlaments formed
were visibly similar by transmission electron microscopy
(Supplementary Fig. 1) and aggregation rates were similar
(Supplementary Fig. 2). We ﬁrst measured the overall
progression of the association reaction using ThT ﬂuorescence
and soluble protein concentrations. Under these conditions,
ﬁlament formation is B90% complete within 3 h (Fig. 2b).
A single-molecule ﬂuorescence resonance energy transfer
(FRET) approach was then used to observe any oligomeric
species18. An equimolar mixture of A488-K18 and A647-K18 was
incubated under ﬁlament-forming conditions. At various points
throughout incubation, aliquots were removed and diluted to
concentrations suitable for single-molecule ﬂuorescence analysis.
These solutions were then pumped under continuous ﬂow
through a microﬂuidic channel mounted on a microscope
slide22 (Fig. 2). A blue (488 nm) laser beam was focused to a
diffraction-limited confocal spot within the centre of the
microﬂuidic channel, leading to the excitation of A488-K18.
Under these conditions, A647-K18 monomers were undetectable,
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Figure 1 | Cartoon of the full-length tau sequence, showing the major
regions and location of the K18 sequence. Tau is alternatively spliced
in vivo, with two possible inserts near the N terminus (N1 and N2) and one
in the carboxyl-terminal half (R2). Repeats 1–4 (R1—R4), each 31 or 32
residues, represent the core of the ﬁlaments. The amino-terminal half of tau
is termed ‘projection domain’ because it does not bind to the microtubule
wall. The point deletion DK280 (indicated in red) located in one of the two
hexapeptide motifs responsible for aggregation of tau into ﬁlaments43, and
the substitution P301L (indicated in purple) that occur in FTD strongly
enhance the b-sheet-forming propensity. The anti-aggregant PP mutant
contains two substituted proline residues at positions I277 and I308
(indicated in blue). The K18 construct11, consisting of the four repeat
regions, has been adapted for this work through three mutations—C291A
and C322A (black dots) and I260C (black star) to allow speciﬁc
ﬂuorophore Alexa labelling at position 260 using maleimide chemistry.
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whereas A488-labelled monomers resulted in a single ﬂuorescent
burst in the blue channel. Oligomers containing both the labels
were detected as bursts in the red channel, since any A647-K18 in
close proximity to A488-K18 can be indirectly excited via FRET.
We used this approach to quantify the proportion of the soluble
(monomeric and oligomeric) material that was oligomeric. The
vast majority of species observed were monomeric throughout the
reaction. However, after only 0.5 h, whereB95% of tau remained
soluble, there was an increase in the number of oligomers
(Fig. 2c), representingB0.1 % of the detected soluble tau species
by number (Fig. 2c, inset). Most of the oligomers were only
slightly brighter than the average monomer, and thus presumably
relatively small. We estimated their apparent size by comparing
the intensity of the oligomer ﬂuorescence with that of a
monomer, making the assumption that there was no signiﬁcant
quenching in the oligomeric species (see Methods)18. Pooling of
all the data revealed that these small oligomers are most highly
populated during the timeframe over which the ﬁlaments are
formed and extended (Fig. 3, Supplementary Fig. 3). After B3 h,
the majority of ﬁlament formation had taken place, and the
oligomer concentration appeared stable.
Observation of such a lowly populated species, which would
certainly not be detected using traditional ensemble based
methods, demonstrates the remarkable sensitivity of the techni-
que for the early stages of the aggregation process. However, since
the overall proportion of soluble tau in oligomers was so low, we
took steps to ensure that we were detecting true oligomers in our
experiments by examining an ‘anti-aggregant’ mutant form of tau
as a negative control. The K18-PP mutant has two proline
residues introduced by substitution (I277P and I308P) to reduce
its b-sheet-forming propensity and is reported in the literature to
prevent tau aggregation23. Immediately following initiation of the
reaction, the concentration of oligomers detected was around just
0.1 nM, as compared with typical oligomer concentrations of
5 nM detected for wild-type K18, conﬁrming that we are
observing true oligomers in our experiments with wild-type tau
(Fig. 4). Surprisingly, on incubation under our standard
conditions, the number of oligomers detected increased steadily
and signiﬁcantly throughout the monitoring period of 8 h
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Figure 2 | Aggregation of K18 under standard ﬁbril-forming conditions followed using single-molecule FRET. (a) Diagram of microﬂuidic channel
(upper) and single-molecule FRETset-up (lower) used in this work. (b) Bulk aggregation kinetics for the ﬁlament formation of K18 (left-hand axis). Soluble
tau concentrations of A488-K18 and A647-K18 during the experiment. The dotted line represents the remaining soluble concentration of unlabelled
K18 after 24 h when it is incubated under the same conditions (right-hand axis, green line). Formation of ﬁlaments by A647-K18 monitored by ThT
ﬂuorescence. (c) Number of detected oligomers throughout the aggregation. The inset is the fraction of soluble tau in oligomers, according to burst rates.
Aliquots of reaction mixture were diluted rapidly and subjected to single-molecule FRETanalysis. In b,c, each point represents the average of —three to ﬁve
individual measurements, and the error bars the s.d.
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Figure 3 | Number density plots showing the evolution of the apparent
oligomer size of A488/A647-K18 and mutants at different incubation
times. Oligomers remain small throughout the reaction, with no observed
especially stable sizes. Numbers reported are the total of each oligomer
size recorded during the —three to ﬁve replicate experiments.
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(Supplementary Fig. 4, Po0.0001), though at a much slower rate
than that observed for wild-type tau, and without any apparent
formation of ﬁlaments. Since we have not observed any ﬁlament
formation, we do not know if these oligomers are of the same
kind as those seen for K18-wt, or indeed if they are on- or off-
pathway; however, we note that they share a common size
distribution with K18-wt (Fig. 3).
Disaggregation of K18 tau paired helical ﬁlaments. We also
investigated the dissociation process of the labelled ﬁlaments
formed under our standard aggregation conditions to demon-
strate that the aggregation reaction was reversible. Filaments of
A488/A647- K18 were collected by centrifugation, and fresh
buffer added on top to initiate dissociation. The concentration of
soluble tau increased with incubation time as the equilibrium
between ﬁbrillar and soluble tau was re-established. Immediately
following dilution of the sample, a relatively large proportion
(0.6–3 %) of the soluble tau was oligomeric (as compared with 0.1
% observed during aggregation); however, this proportion
decreased rapidly during the ﬁrst 24 h after dilution as the
monomeric concentration increased, despite the overall oligo-
meric concentration increasing steadily over 1 month (Fig. 5).
The oligomers observed in this experiment were nearly all small,
consistent with the species being populated towards the end of
the aggregation experiments.
Aggregation of two aggregation-prone K18 tau mutants.
Having established a methodology, similar aggregation experi-
ments were performed with the aggregation-prone deletion
mutant of the K18 construct, K18-DK280. The aggregation reac-
tion took place faster under the same conditions as K18 (Fig. 4a),
as has previously been reported20, being largely complete within
1–2 h, so we changed the separation of the data points accordingly.
Again, the majority of soluble species were monomeric (Fig. 4).
The total number of detected oligomers peaked at 0.5 h, during the
ﬁlament growth phase, and thereafter decreased, but remained
higher than the number observed for K18-wt, even towards the
end of the reaction. At peak, there were around 50 times
more oligomers observed than for K18, whereB4 % of the species
detected were oligomeric (Fig. 4b). Owing to their larger
population, we are better able to characterize the oligomers for
this version of K18 tau, as demonstrated by the contour plots of
the number distribution for K18-DK280 (Supplementary Fig. 3b).
Similar to K18-wt, the vast majority of the observed oligomers
remain small throughout the reaction (Fig. 3). We did not observe
any peaks in the intensity distribution that would have suggested
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Figure 4 | Nucleation–conversion–polymerization description of tau aggregation. (a) Coarse-grained on-pathway conversion model obtained from
theoretical considerations (Supplementary Material). Initial formation of non-growth-competent oligomeric species x(t), of average length xa(t), occurs via
a reaction of order nc in monomer concentration m(t). Formation of ﬁbrils f(t), of average length fa(t), then proceeds via addition of monomer units in a
reaction of ﬁrst order in m(t). Rate constants (k) for these processes and their corresponding reverse reactions are labelled. (b) Oligomeric and (deduced)
ﬁbrillar concentrations during the aggregation of K18, K18-PP, K18-DK280 and K18-P301L tau. Data represent the average of —three to ﬁve independent
experiments, and error bars indicate the s.d. of these. Best ﬁts for coarse-grained nucleation–conversion–polymerization description for K18, K18-DK280
and K18-P301L are shown as solid lines. The dotted black curves indicate upper bounds for x(t) predicted from the simpler inadequate nucleation–
polymerization model (see Methods).
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especially stable oligomer sizes; however, a small concentration of
brighter species appear as the reaction proceeds and ﬁbrils are
created (Supplementary Fig. 3b). This could represent an increase
in the average size of the oligomers or ﬁbrils passing through the
edges of the confocal spot, but represents a minority of the
detected events.
Further aggregation experiments were then conducted with
another mutated version of K18 associated with FTDP-17,
K18-P301L. Oligomer concentrations reached a rapid peak
B0.5 h after initiation of around—three to four times that
observed for K18-wt, remaining high for some time before
decreasing slowly as ﬁbrils were formed (Fig. 4b). The oligomer
size distribution is very consistent over the ﬁrst few hours when
few ﬁbrils are present in the reaction mixture and oligomer
concentrations are high, and strongly resembles those from both
K18-wt and K18-DK280 (Fig. 3).
The larger concentrations of oligomers formed by the
K18-DK280 mutant also allowed us to assess their stability on
dilution. Oligomer-‘rich’ samples were prepared by incubating
K18-DK280 for 30min under our standard conditions, and
changes in the oligomer concentration following dilution were
then monitored through the oligomer burst rate. The results of
this experiment showed that some oligomers were dissociating
throughout our typical measurement times, but that our
estimated concentrations were underestimated by at most a
factor of two (Supplementary Fig. 5).
Since earlier publications have reported on the toxic nature of
small b-sheet-rich tau oligomers to the neuronal cell line
SH-SY5Y24–26, we tested our samples of oligomer-containing
K18-DK280 for such toxicity using a similar approach.
Application of oligomers to the cell samples resulted in no
detectable toxicity (Supplementary Fig. 6) even though we found
the oligomers to be stable in cell culture medium throughout the
incubation times used (Supplementary Fig. 7), possibly due to the
tau in our experiments not being full length.
Oligomeric species are observed for all K18 tau types, and their
formation broadly precedes ﬁbril formation in aggregation
reactions, with oligomer populations sequentially rising and
falling before bulk depletion of monomer. Therefore, a key
mechanistic question asks how the different timescales and
amplitudes of the processes are related. A simple nucleation–
polymerization model16,17,27,28, treating oligomers as small
ﬁbrils, cannot describe the observed oligomer population
amplitudes while permitting the observed formation of long
ﬁbrils (Supplementary Fig. 8 and Online Methods). However, if
oligomeric species are considered to be structurally distinct from
small ﬁbrils, the necessary introduction of an on-pathway
conversion reaction successfully describes the reaction kinetics,
for both the K18 construct and the DK280 and P301L mutants
(Fig. 4).
Qualitative comparison of observations for K18 and its mutant
versions highlights major differences between their kinetics.
Oligomers are more highly populated for both (disease-
associated) mutants, K18-DK280 and P301L. The overall time-
scales for the reactions are also different, for both the emergence
of oligomers and ﬁlament accumulation. In the case of
K18-DK280, the reaction reaches completion after B2 h
compared with 4 h for K18, whereas the ‘anti-aggregant’ PP
mutant, displays no noticeable accumulation of ﬁbrils within 8 h.
It is also of note that although oligomers may have been observed
for the ‘anti-aggregant’ PP mutant, the oligomer concentrations
have still not reached their peak within 8 h, suggesting that the
nucleation rate constant is much lower for this mutant. In
contrast, peak oligomer concentrations are reached rapidly for
P301L and K18-DK280, suggesting that nucleation is signiﬁcantly
more favourable for these mutant tau species in comparison with
wild type. We sought to describe these results in a more
quantiﬁable fashion. Detailed quantiﬁcation of these differences is
made possible by numerically ﬁtting our simple conversion model
where monomers associate to form oligomers (of the apparent
size observed in our experiments) in a heparin-dependent
manner, and are subsequently converted into ﬁbrillar species
(Fig. 4a). Fitting to each of the data sets allowed the extraction of
all relevant rate constants (Fig. 4b, Supplementary Table 1), and
subsequently the changes in the activation free energy introduced
on mutation for each reaction step, as described in Methods and
summarized in Table 1. Since we had observed that there was
some dissociation of oligomers during our measurements, we
established that the estimated activation free energy changes were
insensitive to the exact oligomer concentrations, that is, values
did not change within error when all oligomer concentrations
were doubled (see Methods). Although several mutation effects
are apparent, the most striking one is the large increase in the
initial nucleation rate on DK280 mutation. This effect primarily
explains the higher number of oligomers observed for
K18-DK280 aggregation, and is likely to reﬂect reduced
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Figure 5 | Fibrils formed from A488-K18 and A647- K18 tau
disaggregate slowly into oligomers and monomers. (a) Soluble
concentrations of A488-K18 were estimated using the burst rate in the
donor channel from smFRET measurements. (b) The proportion of events
due to oligomeric K18 decreases with incubation time, although the
estimated total number of oligomers within the solution increased. (c) Three
independent experiments were performed (open, ﬁlled and crossed
symbols), the initial ﬁlament mass was similar but not identical in each.
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electrostatic repulsion between monomers due to its reduced
overall charge in comparison with K18 and/or its greater
propensity to form b-structure23. The 50-fold increase in
oligomer population only results in an approximately twofold
reduction in the timescale of ﬁbril formation, suggesting an
additional effect of the mutation of the transition from oligomers
to ﬁbrils. Accordingly, the activation free energy for ﬁbril
formation from oligomers also increases on mutation.
Similar results were also obtained for the P301L mutant, with
nucleation (and denucleation) rates being increased, but ﬁbril
elongation (and shortening) rates being decreased compared with
wild type (Table 1). Although appropriate for early times, the ﬁt
for this mutant does not describe the later stages of the
aggregation process so successfully, indicating the possible
presence of additional processes not included in our simpliﬁed
scheme. However, it remains useful for comparative purposes, so
has been used to make approximate quantitative predictions
alongside the other proteins studied. Although we are not able to
extract reliable estimates for all rate constants for K18-PP, we can
make a robust estimate of the change in the nucleation rate on
mutation and this is signiﬁcantly reduced (Table 1).
Discussion
Interestingly, the two mutants with increased b-sheet-forming
propensity display increased nucleation rates, but reduced ﬁbril
elongation (and shortening) rates, while the mutant with
decreased b-sheet-forming propensity (K18-PP) has a reduced
nucleation rate. Although we observed no apparent toxicity (by
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) or lactate dehydrogenase assays of K18 oligomers on
incubation with neuronal cells in our model system
(Supplementary Fig. 6) it is possible that these standard assays
are too coarse to detect an effect. A recent study has shown tau
oligomers to have more subtle effect by decreasing dendritic spine
density of differentiated neurons29. We note that the nucleation
rates we observed appear to correlate with aggregation of tau
within the brain in inducible transgenic mice systems30,31.
There are several studies based on ensemble methodologies, such
as light scattering or ThT ﬂuorescence, of the effect of mutation in
tau on aggregation kinetics. These studies are fundamentally quite
different to that presented here because these methods being
(broadly) sensitive to ﬁbril concentration best report on the later
stages of aggregation, rather than the earlier stages addressed here.
Nonetheless, we have found that many of our results recapitulate
these earlier ﬁndings. For example, it has been suggested that the
DK280 mutation leads to an increased nucleation rate and an
enhanced overall aggregation kinetics10. Similarly, consistent with
the literature, we did not observe any decrease in the concentration
of soluble K18-PP tau throughout our measurements. We were,
however, able to observe some oligomers, whose number increased
during our monitoring period, but still remained lower (1/5th–1/
10th) than for the wild-type protein. In general, it is agreed that
P301L aggregates faster than wild-type tau20,32 and it has previously
been suggested for full-length tau that this is due to faster ﬁbril
elongation33,34. Under the conditions used here, we observed that
despite
the rapid formation of oligomers, the reaction approached steady-
state more slowly on P301L mutation due to a reduction in the ﬁbril
elongation rate constant. There are differing reports of the effect on
nucleation, all based on full-length tau, with suggestions that the
mutation enhances32,33, or retards34 the process. Our technique,
highly sensitive to small oligomeric species, has demonstrated that
the nucleation rate is in fact increased due to the mutation, at least
in the context of the K18 repeat construct.
It is well known that ‘seeding’, the addition of preformed
ﬁbrillar or oligomeric structures, generally increases the rate of
aggregation in a number of systems, and this has been observed
in vitro for tau26,35,36. However, experimentally quantifying this
effect is challenging due to the difﬁculty in determining the
concentration of these initial seeds. These complications are
particularly prominent for oligomeric seeding due to added
difﬁculties in detecting oligomer populations in general.
Theoretical modelling thus provides a powerful alternative
approach, allowing order-of-magnitude estimates for system
properties that are experimentally inaccessible, via careful
extrapolation of observations. On the basis of the general
conversion model and ﬁt parameters described in Fig. 4, we can
estimate the concentration of oligomeric seeds required to
double the rate of ﬁbril formation under the experimental
conditions described. By following the procedure described in
Supplementary Material, we arrive at estimates of 0.01 mM for
K18, 0.3 mM for K18-DK280 and 0.2 mM for K18-P301L. The
difference in values reﬂects the extent to which the initial
nucleation step limits the overall aggregation reaction for each tau
construct; for K18, it represents an important bottleneck in the
ﬂow of mass from free monomer to ﬁbrils, thus a relatively small
contribution to this step via seeding has a larger overall
effect. Similarly, we are able to estimate the effects of seeding
under conditions of compartmentalization, one of a myriad of
complicating factors that occur in the cellular environment. For a
typical neuronal cell volume of 6,000 mm3 at a tau concentration
of 2 mM, the reaction half-time for K18 can be halved from an
estimated 4 to 2 h by extremely low numbers of oligomers; B30
oligomers sufﬁce, under the assumption that the nucleation
reaction is of second order in monomer such that nc¼ 2. This
indicates that only a very small number of seeds would need to be
transferred from cell to cell for spreading of oligomers via a
prion-like mechanism37,38, in an idealized situation without
inhibition by cellular chaperones. For K18-DK280 and P301L
under the same conditions, B2,000 oligomers are required to
approximately halve the reaction half-time from 4 to 2 h and 300
to 150 h respectively. Spreading is thus potentially less efﬁcient for
K18-DK280, although a 100-fold higher concentration of
oligomers, and a fourfold higher mass of ﬁbrils, could be
present in the cell as compared with K18, increasing the
probability of cellular damage and death. Although these
calculations are based on a shortened construct of tau and
therefore miss much of the complexity of the biological situation,
these calculations may be instructive in understanding the
dynamics of spreading. These results are particularly compelling
in light of recent results demonstrating differential spreading of
tau isoforms between neurons in vivo21. Following injection of
lentiviral particles encoding tau, pathology development for wild-
type tau was spread throughout neurons connected to the
injection site, whereas pathology associated with P301L tau was
restricted to cells close to the injection site despite the higher level
of neuronal death observed in the latter case21.
Table 1 | The effect of mutation on the four different
activation free energies according to a simple oligomeric
conversion model for tau aggregation.
Protein kn kˇn kþ koff
DK280 4.9±0.7  1.5±0.7 þ 2.5±0.6 þ 1.7±1.0
P301L  2.7±0.7  1.8±0.7 þ 3.1±0.8 þ4.6±1.1
PP 4.1±0.7 ND ND ND
ND, not determined; PP, I277P I308P mutant.
The change in activation energies (from K18-wt) for the forward and backward processes of
nucleation to form oligomers from monomer (kn and kˇn) and the conversion of oligomers into
ﬁbrils (kþ and koff) are reported in units of RT for each mutant.
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In summary, we have combined single-molecule ﬂuorescence
and kinetic analysis to determine the aggregation pathway for the
tetra-repeat K18 tau construct and two disease-related mutants,
allowing us to determine how the mutation alters the aggregation
pathway. Our quantitative kinetic model with microscopic rate
constants allows us to show that seeding may be highly effective
in the cellular environment, providing support for the prion-like
spreading model. This could serve as a general approach to
determine the critical molecular events that lead to the formation
of potentially toxic oligomers, and additionally enables the
number of oligomers and aggregation rate to be estimated under
conditions that are not accessible experimentally.
Methods
Chemicals. Thioﬂavin T, ammonium acetate and bovine serum albumin (BSA)
were all purchased from Sigma. AlexaFluor-488 C5 and 647 C2 maleimide and
Vybrant MTT Cell Proliferation Assay Kit are produced by Molecular Probes.
Heparin 3,000 was obtained from MP Biomedicals.
K18 and mutant K18 constructs. To ensure speciﬁc labelling, the two natural
cysteine residues at positions 291 and 322 (in R2 and R3) were mutated to alanine,
and a cysteine was introduced at position 260. This enabled ﬂuorophore labelling of
the protein without introducing bulky residues in the repeat domain responsible
for aggregation. The construct (K18-C291A/C322A/I260C) was expressed in E. coli
as described previously6, and labelled with either AlexaFluor-488 or AlexaFluor-
647 using maleimide chemistry. Mass spectroscopy, SDS–polyacrylamide gel
electrophoresis (SDS–PAGE) and analytical size exclusion all showed the protein
labelling to have been successful, and the material to be apparently free of
preformed aggregates (Supplementary Fig. 1). The aggregation rate of A647-K18
and A647-K18-DK280 were similar to that of unlabelled K18 and K18-DK280 in
the presence of dithiothreitol (Supplementary Fig. 1). Described mutations were
achieved through site-directed mutagenesis.
Aggregation of tau constructs. We employed the same standard aggregation
conditions in all our assays to ensure comparability. Solutions of 10 mM K18
construct in 50mM pH 7.0 ammonium acetate were incubated undisturbed at
37 C, in the presence of a 1:4 molar ratio of heparin (MW 3000) as an initiator.
Thioﬂavin T measurements of tau aggregation. K18 construct was incubated
under standard aggregation conditions in the presence of 20 mM Thioﬂavin T and
5mM dithiothreitol in untreated half-area 96-well plates (Corning). The ﬂuores-
cence intensity throughout incubation was monitored using a FLUOstar ﬂuores-
cence platereader (BMG Labtech, Offenburg, Germany).
Soluble tau concentrations. In aggregation studies, soluble protein concentra-
tions were monitored by periodic removal of aliquots, and 400-fold dilution, fol-
lowed by SDS–PAGE analysis. Fluorescence imaging of gels (using a Typhoon Trio,
GE Healthcare) was used to quantify band intensity. Concentrations were calcu-
lated by comparison with the band intensity of the starting mixture, which was
known to be 5 mM A488-K18 and 5 mM A647-K18. The ﬁnal concentration of
soluble tau (roughly 5 mM) also matched that found for the unlabeled construct
from SDS–PAGE analysis and Coomassie staining (Fig. 2b, dotted line). In
aggregation studies of K18-DK280, K18-P301L and K18-PP and disaggregation of
K18, the burst rate in the donor channel (using an event threshold of 10) from
single-molecule measurements was used as a probe of the concentration of soluble
A488-K18. This approach was validated by comparison with results from quanti-
tative SDS–PAGE analysis.
Single-molecule FRET measurements of K18 aggregation. Aliquots of aggre-
gating mixtures of equimolar A488-K18 and A647-K18 were removed periodically
without disturbing the pellet and diluted 50,000-fold into 50mM pH 7.0 ammo-
nium acetate buffer containing 0.1mgml 1 BSA and 2.5 mM heparin (average
MW 3,000). After dilution, the solutions were loaded into a gel-loading tip attached
to the inlet of a simple one-channelled PDMS microﬂuidic device measuring 25 mm
in height and 100 mm in width, as described previously22. Sample was passed
through the channel by withdrawing solution from the device at the outlet channel
at a ﬂow rate of 0.5 cm s 1 (achieved by attaching the outlet to a syringe pump
(PHD2000, Harvard Apparatus)). The device was mounted onto a home-built
single-molecule confocal instrument, described in detail previously39. In brief,
488-nm laser light at an intensity of 2mW was directed through the back port
of an inverted microscope (Nikon Eclipse TI) where it was reﬂected by a dichroic
mirror (FF500/646-Di01) through an oil immersion objective (Nikon CFI Plan
Apochromat VC 60X Oil N2 NA 1.4, W.D 0.13mm), which focuses it to a
diffraction limited confocal spot within the microﬂuidic channel. The emitted
ﬂuorescence is collected by the same objective and passes through the dichroic
mirror, before being focused by a tube lens within the microscope body through a
50 mm pinhole (Thorlabs). A dichroic mirror (585DRLP Horiba) then separates the
ﬂuorescence from the two different ﬂuorophores; the longer wavelength passes
through the dichroic and is focused by a lens (Plano apo convex, focal
length¼ 50mm, Thorlabs) through a band-pass and long-pass ﬁlter 565ALP/
695AF55 (both Horiba) onto the Avalanche Photodiode (APD) detector. The
shorter wavelength is reﬂected by the dichroic and is focused through a long-pass
and band-pass ﬁlter 535AF45 (Horiba)/540LP (Omega optics) onto the second
APD. Outputs from the two APDs are connected to a custom-programmed ﬁeld-
programmable gate array, FPGA (Colexica), which counts the signals and
combines them into time bins of 100 ms, which matches the expected residence
time of the molecules in the confocal volume.
Analysis of single-molecule FRET aggregation measurements. The time-bin-
ned data were analysed using custom-written software in Igor Pro (Wavemetrics),
which corrects for both autoﬂuorescence and cross-talk.
The total number of events (monomeric and oligomeric) due to donor (A488)-
labelled tau was determined by counting the number of bursts that exceeded 10
counts per bin in the donor channel and used to determine the concentration of
soluble donor-labelled tau (by comparison with a solution of known tau
concentration, that is, immediately after initiation of the reaction). This approach
was validated by cross-checking against SDS–PAGE gels of pelleted samples (see
soluble tau concentrations, Methods).
Oligomeric events were then identiﬁed as bursts that exceeded 10 counts per bin
in the acceptor channel since monomeric tau labelled with either donor or acceptor
(A647) would not appear in this channel. We performed experiments to assess the
stability of the oligomers during our measurement procedure. ‘Oligomer-rich’
samples were generated by incubating K18-DK280 for 30min using our standard
conditions and then diluted for (20min) single-molecule ﬂuorescence
measurements. Under these conditions, the oligomer concentration is high enough
to examine the oligomer burst rate throughout the measurement. Oligomer
concentrations were found to gradually decrease throughout the measurement time
within buffers containing BSA (used in our dilution buffer to prevent adsorption of
labelled tau to surfaces); however, this affects the overall estimated concentration
by less than a factor of two (Supplementary Fig. 5) and does not affect our
estimates of the changes in activation energies. It is possible that unstable
oligomers, which dissociate within the dead-time of our experiment (a few
minutes), are also present in the aggregation reaction mixture; however, such
unstable species seem unlikely to impart toxicity and are not required to create a
mechanistic model that describes the data. Oligomer concentrations (by number,
not mass) were estimated by multiplying the soluble concentration of tau (which is
predominantly monomeric) by the proportion of detected events attributed to
oligomers. A minor fraction of very intense events spanning multiple time bins was
observed in a minority of K18 samples at late time points where sedimented ﬁbrils
had been disturbed and was ascribed to ﬁbrillar fragments. To focus on soluble
oligomers, these events were excluded from the analysis. Sedimentation was
observed reproducibly for K18-wt samples a few hours after initiation of
aggregation, but not for any of the K18 mutants. To check that oligomers were not
being sequestered within an insoluble fraction and disturbing our analysis, we
performed a control experiment where K18 was aggregated as previously but under
conditions of continuous shaking to avoid sedimentation. Both the equilibrium
monomer concentration and the oligomer concentrations were largely unaffected
indicating that the oligomers were not being removed from the solution
(Supplementary Fig. 9).
For each of the oligomeric events, the apparent size was calculated by
combining the intensity remaining in the donor channel with that transferred to
the acceptor channel (after application of a correction factor, g, to account for the
different quantum yields and detection efﬁciencies in the two channels) and
comparing this with the average intensity of monomeric events observed in the
donor channel. We have used this approach previously18, the apparent size being
calculated using equation (1)
Apparent oligomer size ¼ 2 I
0
D þ I0A

g
oID4
 
ð1Þ
where I0D and I
0
A correspond, respectively, to the intensity in the donor and
acceptor channels for the oligomeric event,oID4 represents the average intensity
of donor labeled monomers in the donor channel, and the factor of 2 accounts for
the fact that on average each oligomer is composed of only 50% donor-labelled tau.
Although this last assumption is true on average, it is not true for all oligomers, and
this acts to broaden estimated size distributions, particularly for small oligomers.
We have previously seen good agreement between size distributions estimated
using this approach and for the same oligomers immobilized on surfaces40.
Following these calculations, events were binned by apparent oligomer size (bin
width¼ 1) and FRET efﬁciency (bin width¼ 0.05), where the FRET efﬁciency is
calculated according to equation (2):
FRET efficiency ¼ I
0
A

g
I0D þ I0A

g
ð2Þ
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Single-molecule FRET measurements of ﬁlament dissociation. Labelled K18
ﬁlaments were prepared using the standard aggregation conditions, and then
puriﬁed by four cycles of centrifugation where the pellet was washed by replace-
ment of the supernatant with fresh 50mM pH 7.0 ammonium acetate buffer.
Following the ﬁnal wash, 40–65 ml of fresh buffer was carefully pipetted above the
pellet without disrupting it. Aliquots of solution (away from any pellet) were
removed periodically, rapidly diluted into 50mM pH 7.0 ammonium acetate and
placed on BSA-treated microscope slides (not assessed under ﬂow conditions).
These experiments were performed using a different instrument to the aggregation
assays. The set-up, experimental and data analysis protocols have been described in
detail previously18,39, and were subject to only the following minor modiﬁcations.
The 488-nm laser was used at a power of 80–90 mW. We identiﬁed bursts above a
threshold of 7 photonsms 1 bin in the acceptor channel as being due to
oligomers. In support of this approach, buffer-only controls analysed in this
manner typically resulted in onlyB1 % of the number of events as those detected
in dissociation reactions.
Cell culture thiazolyl blue tetrazolium bromide (MTT) assay. SH-SY5Y cells
(from the European Collection of Cell Cultures) were cultured at 30 103 cells per
well in a 96-well plate in DMEM supplemented with 10% (v/v) fetal calf serum, 1%
(v/v) penicillin/streptomycin in a 5% CO2 environment at 37 C for 24 h. After
24 h, the medium was replaced with 50ml of fresh culture medium. Samples of
K18-DK280 were aggregated using the standard conditions to result in maximal
concentration of oligomers (0.5 h for K18-DK280). Dilutions of K18-DK280 were
made up in DMEM and then 50ml of sample was added to each well. A positive
control of 5mM Staurosporin and negative controls of HBSS and medium alone were
also added to the cells. The cells were left to incubate for 4 h in a 5% CO2 environ-
ment at 37 C. The media were then removed and 100ml of fresh medium was added
to each well. Ten ml of 12mM MTT stock solution was then to each well and
incubated at 37 C for 2 h. All but 25ml of medium was then removed from the cells
and 50ml of dimethylsulphoxide was added to each well and mixed thoroughly with a
pipette. The cells were then incubated for 10min at 37 C. The plates were shaken for
1min and absorbance at 540 nm for each sample determined with a FLUOstar
Optima plate reader (BMG Labtech). Absorbance values of SH-SY5Y cells in
different experimental conditions were normalized against cells treated with
DMEM media.
Failure of classical nucleated polymerization theory. The classical theory of
nucleated polymerization27,28 provides a simple yet extraordinarily powerful
description of aggregating ﬁlamentous systems. With only minor modiﬁcations,
this framework has led to successful descriptions for the kinetics of a wide range of
proteins16,27,28,41,42. A notable simpliﬁcation that renders these models so useful is
the identiﬁcation of only two species in the reaction pathway: monomers and
ﬁbrils. Any oligomeric species are treated simply as small ﬁbrils, and off-pathway
reactions are neglected.
The master equation describing the kinetics of a nucleation–polymerization
reaction is illustrated in Fig. 5, and reads
_f j; tð Þ ¼dj;ncknm tð Þnc þ 2kþm tð Þf j 1; tð Þ 2m tð Þkþ f j; tð Þ
 2kof f f j; tð Þþ 2koff f jþ 1; tð Þ;
ð3Þ
where dx,y denotes the Kronecker symbol. The critical nucleus size is denoted nc,
with a corresponding nucleation rate constant kn; nc represents the number of
monomer residues that make up the smallest stable aggregate. Although heparin
plays an important catalytic role in the nucleation reaction, its effects are included
in the nucleation rate constant. The symbol m tð Þ ¼ m 0ð Þ P1j¼nc jf ðj; tÞ denotes
the concentration of free monomer as a function of time, with m(0) denoting the
initial monomer concentration; 10 mM for all experiments here. The concentration
of ﬁbrils containing j monomeric residues is denoted f(j, t), with f(j, 0)¼ 0 for all
jZnc and f(j, t)¼ 0 for all jonc. Fibril elongation is described by the rate constant
kþ , with dissociation of monomer from ﬁbril ends governed by koff; the factor of 2
allows for two free ends per ﬁbril. Both elongation and dissociation rate constants
are thus assumed independent of ﬁbril length.
With careful treatment of boundary terms16,17, equation (3) can be summed to
yield an expression for the zeroth moment of the ﬁbril length distribution,
P tð Þ ¼P1j¼nc f ðj; tÞ:
_P tð Þ ¼ knm tð Þnc : ð4Þ
We can formally integrate equation (4) to give
P tð Þ ¼ kn
Zt
0
m t0ð Þnc dt0; ð5Þ
representing the total concentration of aggregates as a function of time.
Supplementary Fig. 8b–d illustrates how equation (5) can be used to obtain an
upper bound for the average aggregate length distribution within this framework
that is consistent with the kinetic available data for each K18 tau construct. For
each data set, the time series for m(t) can be inferred experimentally from
measurements of the total concentration of soluble tau species, accounting for the
known proportion of which is accounted for by oligomers (see Figs 3 and 4). The
resulting numerical function is linearly interpolated (Supplementary Fig. 8b) and
integrated to ﬁnd P(t) as per equation (5), with kn set to the smallest possible value
that ensures P(t) accounts for observed oligomer populations (Supplementary
Fig. 8c). This lower bound for P(t) is then used to obtain an upper bound for the
average aggregate length m(t) as a function of time (Supplementary Fig. 8d), via the
relation
m tð Þ ¼ m 0ð Þm tð Þð Þ=PðtÞ; ð6Þ
where m(0)–m(t) gives the total concentration of monomeric residues
contained within aggregates.
By applying this procedure for a range of plausible critical nucleus sizes
(2rncr10), we show that the maximum plausible average aggregate length
allowed by classical nucleation–polymerization theory falls short of observed tau
ﬁbril lengths formed under these conditions23. In addition, the nc¼ 10 case more
generally demonstrates the failure of any model where monomers only form a
single type of aggregate, provided that the total aggregate concentration does not
decline beyond the time at which the observed oligomer population reaches a
peak. Furthermore, by assuming a reasonable average ﬁbril length of 2,000
monomer units throughout the reaction (a 1-mm ﬁbril with one tau molecule
in each b-strand), the aggregate concentration P(t) can be found numerically
from equation (6), using the experimental time series for m(t). These P(t)
curves thus represent strong upper bounds for the oligomer concentration x(t),
as shown overlaid in dotted black in Fig. 4b. Although at early reaction times
this upper bound is underestimated due to transient smaller initial average
aggregate size, at later times it is clear that classical nucleation–polymerization
does not provide an adequate description. A modiﬁcation to this basic theory is
thus needed to reconcile observed oligomer concentrations with the production
of long ﬁbrils.
Conversion model and ﬁtting. Oligomeric aggregates are now treated as distinct
from ﬁbrils, introducing an additional step in the reaction pathway: oligomers now
exchange both with free monomer via a reaction of order nc in the monomer
concentration, and with ﬁbrils via a reaction of ﬁrst order in monomer con-
centration. Supplementary Fig. 10 and Fig. 4a illustrate this new model, demon-
strating how it is coarse-grained, simpliﬁed and re-expressed in a useable form in
terms of conversions between different species with established average sizes. The
kinetic equations for this simple model read:
_x tð Þ ¼ knm tð Þnc ~knx tð Þ kþm tð Þx tð Þþ koff f tð Þ; ð7Þ
_f tð Þ ¼ kþm tð Þx tð Þ koff f tð Þ; ð8Þ
_m tð Þ ¼ xaknm tð Þnc  fa tð Þ xa tð Þð Þkþm tð Þx tð Þ
þ xa tð Þ~knx tð Þþ fa tð Þ xa tð Þð Þkoff f tð Þ:
ð9Þ
Concentrations of different populations are denoted with the symbols
x(t): oligomeric species,
f(t): ﬁbrils,
m(t): monomers,
where the initial values x(0) and f(0) are 0, and m(0)¼ 10 mM as before.
Heparin dependence is again subsumed into the nucleation rate constant. The
critical nucleus size nc is now taken as nc¼ 2 for simplicity.
The various average lengths of different species, expressed as numbers of
monomeric residues, are given by:
xa(t): average length of oligomers,
fa(t): average length of ﬁbrils
and the various rate constants describe the processes shown in Fig. 4a and
Supplementary Fig. 10b:
kn: heparin-dependent nucleation of monomers to form oligomers,
~kn: complete dissociation of oligomers into monomers,
kþ : monomer-dependent conversion of oligomers to ﬁbrils,
koff: conversion of ﬁbrils back to small oligomers, releasing free monomer.
To conserve mass, the average lengths xa(t) and fa(t) must be constant
with time. The oligomer length, averaged over the full reaction time, can be
determined directly from the available data giving numbers of oligomers
detected of each length. Average ﬁbril length is estimated at 2,000 monomeric
residues per ﬁbril, although the quality of ﬁt is not strongly sensitive to the precise
value chosen.
The functions m(t) and x(t) are ﬁtted directly to populations inferred from the
data presented in Figs 3 and 4, via numerical integration of the kinetic equations.
All ﬁts are numerical, with four rate constants ﬁtted separately to each tau data set
using a global least-squares Levenberg–Marquardt algorithm. The resulting best ﬁts
are shown in Fig. 4b.
Seeding predictions. The effects of seeding are taken into account straightfor-
wardly, by setting the initial population concentrations in equations (7–9) at t¼ 0
according to the nature of the seeds. All rate constants are set according to the
ﬁtting procedure discussed above. For the simulations described in the main text,
we investigate seeding by oligomers; x(0) is set to the initial seed concentration,
while f(0) remains negligible. The rate of aggregation is monitored via the for-
mation of ﬁbril mass; if the unseeded reaction gives a ﬁnal ﬁbril residue con-
centration fa  f(N)¼W, and at time tW/2 has produced a ﬁbril residue
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concentration of W/2, any increase in reaction rate on seeding is quantiﬁed by
considering the time stW/2 at which the seeded reaction produces a ﬁbril residue
concentration of W/2. The seeding required to double the reaction rate is thus
found by setting stW/2/tW/2¼ 1/2. For the K18 wild-type construct, this criterion is
very similar to simply halving the reaction half-time. For the DK280 deletion
mutant, seeding leads to a non-negligible increase in the total ﬁbril mass produced,
thus motivating this more careful deﬁnition. Intracellular conditions are simulated
by setting m(0)¼ 2 mM.
Inferring activation free energies. For a given rate constant k describing a
particular reaction step, the activation free energy DGz of the process at a
temperature T can be inferred from transition state theory44, via the equation
k ¼ GeDGz=ðRTÞ; ð10Þ
where R represents the molar gas constant. The prefactor G has units matching
those of k, and is approximately constant for a given process; it has a weak
temperature dependence that to a good approximation is assumed negligible in the
studied range. The change in activation energy DDGz for a given process on
mutation can thus be found44 independently of G by applying equation (10) to
both the WT (kWT) and the Mutant (kMut) system and subtracting:
DDGz ¼ RT ln kWT
kMut
 
: ð11Þ
The values quoted in Table 1 are thus found by application of equation (11) to
the four different rate constants in the conversion model.
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